Stem cell transplantation and clinical outcome
| Case . | Conditioning regimen . | CD34+cells infused (× 106/kg) . | Engraftment . | aGVHD (grade) . | cGVHD . | Complications . | Outcome . | Survival after SCT (days) . | |
|---|---|---|---|---|---|---|---|---|---|
| Neut . | Plt . | ||||||||
| 1 | CA + CY + TBI | 2.25 (PBSCs + BM) | 18 | 21 | 2 | Eruption, diarrhea | CMV antigenemia | Relapse at testis on | 467+ |
| Herpes zoster, BOOP | day 153 | ||||||||
| 2 | CA + CY + TBI | 2.36 (PBSCs) | 14 | 15 | 1 | Oral aphta | CMV antigenemia BOOP | CR on day 390 | 390+ |
| 3 | BU + CY | 2.46 (PBSCs) | 10 | 13 | 3 | NE | FK506 encephalopathy pneumonia (fungus) | Death on day 67 | 67 |
| 4 | CA + CY + TBI | 1.26 (PBSCs) | 13 | 14 | 1 | — | Capillary leak syndrome CMV antigenemia | Relapse at pericardium on day 88 | 117 |
| Herpes zoster | |||||||||
| 5 | CA + CY + TBI | 3.57 (PBSCs) | 14 | 19 | 2 | — | CMV antigenemia | PR | 105+ |
| Case . | Conditioning regimen . | CD34+cells infused (× 106/kg) . | Engraftment . | aGVHD (grade) . | cGVHD . | Complications . | Outcome . | Survival after SCT (days) . | |
|---|---|---|---|---|---|---|---|---|---|
| Neut . | Plt . | ||||||||
| 1 | CA + CY + TBI | 2.25 (PBSCs + BM) | 18 | 21 | 2 | Eruption, diarrhea | CMV antigenemia | Relapse at testis on | 467+ |
| Herpes zoster, BOOP | day 153 | ||||||||
| 2 | CA + CY + TBI | 2.36 (PBSCs) | 14 | 15 | 1 | Oral aphta | CMV antigenemia BOOP | CR on day 390 | 390+ |
| 3 | BU + CY | 2.46 (PBSCs) | 10 | 13 | 3 | NE | FK506 encephalopathy pneumonia (fungus) | Death on day 67 | 67 |
| 4 | CA + CY + TBI | 1.26 (PBSCs) | 13 | 14 | 1 | — | Capillary leak syndrome CMV antigenemia | Relapse at pericardium on day 88 | 117 |
| Herpes zoster | |||||||||
| 5 | CA + CY + TBI | 3.57 (PBSCs) | 14 | 19 | 2 | — | CMV antigenemia | PR | 105+ |
GVHD indicates graft-versus-host disease; aGVHD, acute GVHD; cGVHD, chronic GVHD; CA, cytarabine; CY, cyclophosphamide; TBI, total body irradiation; BU, busulfan; FK506, tacrolimus; MTX, methotrexate; PBSCs, peripheral blood stem cells; BM, bone marrow; BOOP, brochiolitis obliterans organizing pneumonia; NE, not evaluable; Neut, days to reach neutrophil count > 0.5 × 109/μL; Plt, days to reach platelet count > 20 × 109/μL; CMV, cytomegalovirus; CR, complete remission; PR, partial remission; and —, not observed.